# Voyager Therapeutics, Inc.: overview VYGR · Nasdaq · CIK 1640266 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/vygr.md) · [Financials](/companies/vygr/financials.md) · [Filings](/companies/vygr/filings.md) · [Insiders](/companies/vygr/insiders.md) Latest reported revenue: [$3.2m](/filings/0001640266-26-000006.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001640266-26-000006). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [24.6](/filings/0001104659-25-108846.md) | [6.3 d](/filings/0001104659-26-025197.md) | [6.5](/filings/0001104659-26-057097.md) | [5.2](/filings/0001640266-26-000006.md) | [13.4](/filings/0001104659-25-108846.md) | [15.3 d](/filings/0001104659-26-025197.md) | [2.6](/filings/0001104659-26-057097.md) | [3.2](/filings/0001640266-26-000006.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(56.0%)](/filings/0001104659-25-108846.md) | [(610.1%) d](/filings/0001104659-26-025197.md) | [(536.0%)](/filings/0001104659-26-057097.md) | [(704.3%)](/filings/0001640266-26-000006.md) | [(228.9%)](/filings/0001104659-25-108846.md) | [(195.2%) d](/filings/0001104659-26-025197.md) | [(1167.4%)](/filings/0001104659-26-057097.md) | [(833.9%)](/filings/0001640266-26-000006.md) | | Net margin | % | [(36.7%)](/filings/0001104659-25-108846.md) | [(549.3%) d](/filings/0001104659-26-025197.md) | [(479.2%)](/filings/0001640266-26-000006.md) | [(642.0%)](/filings/0001640266-26-000006.md) | [(208.7%)](/filings/0001104659-25-108846.md) | [(178.8%) d](/filings/0001104659-26-025197.md) | [(1077.4%)](/filings/0001640266-26-000006.md) | [(773.2%)](/filings/0001640266-26-000006.md) | | Diluted EPS | $ per share | [(0.16)](/filings/0001104659-25-108846.md) | not reported | [(0.53)](/filings/0001104659-26-057097.md) | [(0.57)](/filings/0001640266-26-000006.md) | [(0.47)](/filings/0001104659-25-108846.md) | not reported | [(0.47)](/filings/0001104659-26-057097.md) | [(0.40)](/filings/0001640266-26-000006.md) | | Free cash flow | $m | [(28.2) d](/filings/0001104659-25-108846.md) | [(14.7) d](/filings/0001104659-26-025197.md) | [(38.6)](/filings/0001104659-26-057097.md) | [(34.4) d](/filings/0001640266-26-000006.md) | [(31.3) d](/filings/0001104659-25-108846.md) | [(30.9) d](/filings/0001104659-26-025197.md) | [(33.4)](/filings/0001104659-26-057097.md) | [(25.8) d](/filings/0001640266-26-000006.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [37.4](/filings/0001558370-24-001988.md) | [40.9](/filings/0001558370-25-002703.md) | [250](/filings/0001104659-26-025197.md) | [80.0](/filings/0001104659-26-025197.md) | [40.4](/filings/0001104659-26-025197.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(196.8%)](/filings/0001558370-24-001988.md) | [(124.3%)](/filings/0001558370-25-002703.md) | [48.8%](/filings/0001104659-26-025197.md) | [(104.1%)](/filings/0001104659-26-025197.md) | [(326.6%)](/filings/0001104659-26-025197.md) | | Net margin | % | [(190.3%)](/filings/0001558370-24-001988.md) | [(113.4%)](/filings/0001558370-25-002703.md) | [52.9%](/filings/0001104659-26-025197.md) | [(81.3%)](/filings/0001104659-26-025197.md) | [(296.5%)](/filings/0001104659-26-025197.md) | | Diluted EPS | $ per share | [(1.89)](/filings/0001558370-24-001988.md) | [(1.21)](/filings/0001558370-25-002703.md) | [2.97](/filings/0001104659-26-025197.md) | [(1.13)](/filings/0001104659-26-025197.md) | [(2.04)](/filings/0001104659-26-025197.md) | | Free cash flow | $m | [(55.1)](/filings/0001558370-24-001988.md) | [(15.0)](/filings/0001558370-25-002703.md) | [74.7](/filings/0001104659-26-025197.md) | [(18.8)](/filings/0001104659-26-025197.md) | [(135)](/filings/0001104659-26-025197.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vygr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $18.1m | 5,172,063 | | Reduced −396,318 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $15.6m | 4,442,951 | | Added +1,014,380 | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $12.0m | 3,436,000 | | Reduced −64,000 | | [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $9.2m | 2,625,000 | | Reduced −377,936 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.2m | 2,345,674 | | Added +62,421 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.7m | 1,330,492 | | Added +280,514 | | [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $4.1m | 1,185,000 | | Added +35,000 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.8m | 1,076,422 | | Added +128,196 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $3.3m | 948,517 | | Added +332,857 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $2.9m | 838,184 | | Reduced −37,384 | ## Recent filings [All 669 filings](/companies/vygr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-21 | 12:07 ET | [8-K](/filings/0001193125-26-427224.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-427224 | | 2026-08-06 | 20:03 ET | [8-K](/filings/0001640266-26-000007.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001640266-26-000007 | | 2026-08-06 | 20:01 ET | [10-Q](/filings/0001640266-26-000006.md) | Quarterly report, period 2026-06-30 | 0001640266-26-000006 | | 2026-07-13 | 12:44 ET | [8-K](/filings/0001104659-26-082906.md) | 8.01 Other events | 0001104659-26-082906 | | 2026-06-10 | 20:05 ET | [8-K](/filings/0001104659-26-072324.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-072324 | | 2026-06-01 | 12:00 ET | [8-K](/filings/0001104659-26-068591.md) | 8.01 Other events | 0001104659-26-068591 | | 2026-05-07 | 20:07 ET | [8-K](/filings/0001104659-26-057115.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-057115 | | 2026-05-07 | 20:04 ET | [10-Q](/filings/0001104659-26-057097.md) | Quarterly report, period 2026-03-31 | 0001104659-26-057097 | | 2026-04-28 | 20:00 ET | [DEF 14A](/filings/0001104659-26-050297.md) | Proxy statement, period 2026-06-09 | 0001104659-26-050297 | | 2026-04-21 | 20:05 ET | [8-K](/filings/0001104659-26-045997.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-045997 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-025197.md), filed Mar 9, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1e8d3c76-0339-4a74-b331-dc1ddf794735) ## About the filer - CIK: 1640266 - Tickers: VYGR - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.